Number of patients oncologists treated with cell and gene therapy has doubled, physician survey finds

Karmanos Cancer Institute becomes first free-standing cancer center to treat hemophilia B with new gene therapy

The Barbara Ann Karmanos Cancer Institute has become the first and only independent cancer center in the U.S. to provide a new hemophilia treatment. Etranacogene dezaparvovec-drlb, also known by its brand name Hemegenix, is a one-time gene therapy approved by FDA for the treatment of adults with hemophilia B.

April 03, 2026

Vol.52 No.13

Drugs & Targets

FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC

FDA approved a label update that will accelerate thaw time for Adstiladrin (nadofaragene firadenovec-vncg), gene therapy for adults with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, enabling an accelerated water-bath thawing method, completed in about 25 minutes, to enhance efficient clinical preparation for healthcare teams.

March 27, 2026

Vol.52 No.12

Cancer Policy

FDA to increase regulatory flexibility for development of cell and gene therapies

FDA has released additional information on its “flexible approach” to regulating chemistry, manufacturing and control, or CMC, requirements for cell and gene therapies.

McKesson oncologist survey report details the state of cell and gene therapy adoption and barriers

Cell and gene therapies are steadily becoming more available to patients, but are still facing systemic hurdles slowing widespread adoption, according to the second annual 2025 “Cell and Gene Therapy Report: Advancing the Future of Medicine,” published by InspiroGene by McKesson. The report draws on new insights from research with physicians and payers, an updated...

October 10, 2025

Vol.51 No.37

Clinical Roundup

Genetic “Trojan horse” selectively kills cancer cells linked to Kaposi’s sarcoma, UC Davis study shows

In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with minimal side effects.

October 03, 2025

Vol.51 No.36

Clinical Trials & Tribulations

An overlooked immune cell population may offer new direction for cell and gene therapy

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.

July 11, 2025

Vol.51 No.27

By Arthur Machlenkin

Number of patients oncologists treated with cell and gene therapy has doubled, physician survey finds

YOU MAY BE INTERESTED IN

Karmanos Cancer Institute becomes first free-standing cancer center to treat hemophilia B with new gene therapy

FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC

FDA to increase regulatory flexibility for development of cell and gene therapies

McKesson oncologist survey report details the state of cell and gene therapy adoption and barriers

Genetic “Trojan horse” selectively kills cancer cells linked to Kaposi’s sarcoma, UC Davis study shows

An overlooked immune cell population may offer new direction for cell and gene therapy

Renew today!

Subscriber content

Never miss an issue!

Login